Ionis Pharmaceuticals Inc (IONS) Stock Analysis
Verdict: HOLD
Pipeline validation and Q2 earnings beats are overshadowed by Alnylam-led sector contagion and heavy insider selling at recent highs.
Investment score: 62/100
Analysis as of
Is Ionis Pharmaceuticals Inc stock worth reviewing? AI model thesis
Ionis is a high-conviction clinical-stage play currently suffering from sector-wide sentiment deterioration despite strong individual fundamental execution.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Ionis Pharmaceuticals Inc opportunities and risks
What speaks for IONS
- Revenue Growth Acceleration
What speaks against IONS
- ATTR Market Saturation Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IONS | n/a | 9.8x | 2.5x | 98.2% | -64.6% | -6.5% |
| KRYS | 44.0x | 24.1x | 47.7x | 92.8% | 53.9% | 2.4% |
| HALO | 28.3x | 6.5x | 18.6x | 76.9% | 23.1% | 6.8% |
| CYTK | n/a | 90.7x | n/a | 90.3% | -784.0% | -5.7% |
| PTGX | n/a | 118.6x | n/a | 99.5% | -154.9% | -1.3% |
| PRAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| Peer median | n/a | 24.1x | n/a | 90.3% | 0.0% | -1.3% |
Frequently asked questions about Ionis Pharmaceuticals Inc (IONS)
Is IONS stock a good investment?
The cached TradeMates AI model rates Ionis Pharmaceuticals Inc as HOLD with an investment score of 62/100. Ionis is a high-conviction clinical-stage play currently suffering from sector-wide sentiment deterioration despite strong individual fundamental execution. This is algorithmic model output, not personal investment advice.
Is IONS stock a buy?
The TradeMates model verdict for IONS is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.